Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use , Antithrombins/adverse effects , Dabigatran/adverse effects , Factor Xa Inhibitors/adverse effects , Factor Xa/therapeutic use , Hemorrhage/drug therapy , Pyrazoles/adverse effects , Pyridines/adverse effects , Pyridones/adverse effects , Recombinant Proteins/therapeutic use , Rivaroxaban/adverse effects , Thiazoles/adverse effects , Administration, Oral , Antibodies, Monoclonal, Humanized/pharmacology , Antithrombins/therapeutic use , Blood Loss, Surgical/prevention & control , Cerebral Hemorrhage/chemically induced , Cerebral Hemorrhage/therapy , Clinical Trials as Topic , Dabigatran/antagonists & inhibitors , Dabigatran/immunology , Dabigatran/therapeutic use , Drug Approval , Emergencies , Factor Xa/pharmacology , Factor Xa Inhibitors/therapeutic use , Hemorrhage/chemically induced , Humans , Pyrazoles/antagonists & inhibitors , Pyrazoles/therapeutic use , Pyridines/antagonists & inhibitors , Pyridines/therapeutic use , Pyridones/antagonists & inhibitors , Pyridones/therapeutic use , Recombinant Proteins/pharmacology , Rivaroxaban/antagonists & inhibitors , Rivaroxaban/therapeutic use , Thiazoles/antagonists & inhibitors , Thiazoles/therapeutic use , United States , United States Food and Drug Administration